Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 120.49% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 120.49% YoY), while the FY2025 annual figure was $721000.0, up 71.26% from the prior year.
• Other Accumulated Expenses was $1.3 million for Q1 2026 at Syndax Pharmaceuticals, up from $721000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.2 million in Q3 2022 to a low of $208000.0 in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $1.0 million across 5 years, with a median of $703000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 1594.68% in 2022, then sank 83.13% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $604000.0 in 2022, then soared by 47.02% to $888000.0 in 2023, then slumped by 52.59% to $421000.0 in 2024, then jumped by 71.26% to $721000.0 in 2025, then soared by 76.14% to $1.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.3 million (Q1 2026), $721000.0 (Q4 2025), and $595000.0 (Q3 2025), per Business Quant data.